Tag Archive for: Series A

Andrew Cawley

Agri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.

Aerial view at EFPL where the technology was established. © EFPL

Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.

Cradle's team. © Cradle

Generative AI protein engineering specialist Cradle NV,  has raised US$24m in a Series A financing round led by Index Ventures w

Quotient Tx' co-founder Inigo Marincorena. © Onur Pinar /Wellcome Sanger Institute

Flagship Pioneering has committed US$50m to launch Quotient Therapeutics that links genetic variation at  cellular level with disease by Nanoseq, a sequencing method licenced from the Wellcome Sanger Institute.

© VectorY Therapeutics BV

Dutch VectorY Tx BV has closed one of this yers’s largest Series A financing rounds in Europe at €129m to push its vecorised antibody pipeline in CNS proteinopathies.

© Vianautis Bio Ltd/ SomaServe Ltd

Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.

Astrocytes superimposed on a brain brighter cropped. © AstronauTx Ltd

Alzheimer’s specialist AstronauTx Ltd has closed a £48m Series A financing to create new treatments for Alzheimer’s diseas

© ??Mogrify Ltd.

British in-vivo cell programming specialist Mogrify Ltd has added US$10m to its US$36m Series A financing.

Anti-CD45RC Abs suppresses the acute immune response by causing the death of harmful CD45RC+ T cells driving (severe) disease in patients. © Aborleris Pharma SA (Zoersel, Nantes

Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.

Herpes simplex vector. © EG 427

Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.